NK:IO
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.
NK:IO
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Status:
Active
Total Funding:
0
Investors List
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - NK:IO
Future Planet Capital
Future Planet Capital investment in Seed Round - NK:IO
More informations about "NK:IO"
Cancer Treatment Reimagined - NK:IO
Unlocking the potential of human Natural Killer cells. NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK …See details»
NK:IO - LinkedIn
? Key highlights: NK:IO is developing a pioneering Natural Killer (NK) cell therapy to address limitations in current cancer immunotherapies Our technology enables unprecedented scale in NK ...See details»
NK:IO - Crunchbase Company Profile & Funding
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics …See details»
NK:IO raises £1.2M, bringing total Seed funding to £5.1M, to …
London, UK, 25 July 2023: NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has …See details»
Imperial spinout NK:IO awarded £1.6M Innovate UK …
London, UK, 11 July 2023: NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, today announced it has been awarded £1.6M in grant funding from …See details»
Natural killer cell therapy under development by new …
Jul 11, 2023 · The company, NK:IO, was founded in 2020 to build on Imperial research, and has launched publicly with the announcement of a £1.6 million Innovate UK grant that it will use to progress its cellular immunotherapy …See details»
NK:IO raises further investment for cell therapy …
Jul 25, 2023 · NK:IO, a new Imperial startup developing a cell therapy for treating solid tumour cancers, has raised an additional £1.2 million in investment, bringing its total seed funding to £5.1 million. The investment will be used to drive …See details»
NK:IO raises £1.2m, bringing total seed funding to £5.1m, to …
NK:IO has raised £1.2M Seed Funding in their latest investment round led by Cancer Research Horizons, to advance its natural killer (NK) cell therapies targeting solid tumours.See details»
NK:IO Raises £1.2M, Bringing Total Seed Funding to £5.1M
Jul 25, 2023 · NK:IO, a leader in natural killer cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2M.See details»
NK:IO awarded £1.6m Innovate UK New Cancer …
11 July 2023 -- London, UK -- NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, today announced it has been awarded £1.6m in grant funding from …See details»
NK:IO Company Profile 2024: Valuation, Funding & Investors
Operator of a biotech company intended to develop novel approaches to natural killer cell-mediated immunotherapy.See details»
NK:IO Appoints Richard Hopkins as CEO, Finalises £5.9m Seed …
Oct 23, 2024 · The £5.9m seed round will accelerate development of NK:IO’s NK cell platform and its lead asset in ovarian cancer. The investment cohort, led by UKI2S, joins Cancer Research …See details»
Nk:io Awarded £1.6M Innovate UK New Cancer Therapeutics Grant …
Jul 17, 2023 · NK:IO is exploiting these discoveries in its unique platform which activates blood stem cell progenitors to yield industry-leading NK cell tumour-killing potency and very high …See details»
NK:IO - Cancer Research Horizons
From these discoveries, NK:IO is developing novel therapeutic candidates targeting hard-to-treat solid tumours, such as ovarian cancer. With over £5M seed funding, NK:IO is advancing its …See details»
An Interview with Keith Thompson – Chair of NK:IO - NK:IO
Keith Thompson is the current chair of biotech start-up NK:IO. He’s also chair of the Pharma Advisory Board of Deep Science Ventures and acted as industry advisor to the Vaccines …See details»
NK:IO - Funding, Financials, Valuation & Investors - Crunchbase
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy.See details»
NK:IO Secures £1.2M in Latest Funding Round to Advance Ovarian …
Sep 12, 2023 · NK:IO, a startup working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has …See details»
NK:IO finalises seed funding to progress ovarian cancer therapy
The recebtly closed £5.9 million seed round will accelerate development of NK:IO’s NK cell platform and its lead asset in ovarian cancer. The investment cohort, led by UKI2S, joins …See details»
News - NK:IO
Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult • NK:IO’s platform, based on pioneering discoveries in NK cell biology, yields industry …See details»
New boss for NK:IO | The Pharmaletter
Oct 2, 2024 · NK:IO, a London-based startup focused on cell therapy for solid tumors, has appointed Richard Hopkins its permanent CEO and completed a £5.9 million ($7.8 million) …See details»